Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5% – What’s Next?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price traded down 7.5% during mid-day trading on Wednesday . The company traded as low as $52.10 and last traded at $51.9140. 216,549 shares were traded during mid-day trading, a decline of 79% from the average session volume of 1,034,382 shares. The stock had previously closed at $56.15.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GPCR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Thursday, January 22nd. JPMorgan Chase & Co. raised their price objective on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, January 22nd. Citizens Jmp lowered their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday. Finally, Stifel Nicolaus upped their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.00.

Structure Therapeutics Stock Down 7.4%

The firm has a market capitalization of $3.68 billion, a PE ratio of -65.80 and a beta of -1.80. The company has a 50-day moving average of $73.19 and a 200 day moving average of $50.24.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently made changes to their positions in the stock. State of Wyoming purchased a new position in Structure Therapeutics in the second quarter worth $28,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. CWM LLC boosted its holdings in shares of Structure Therapeutics by 35.2% in the 4th quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after purchasing an additional 994 shares during the last quarter. Finally, ANTIPODES PARTNERS Ltd increased its position in shares of Structure Therapeutics by 39.1% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock valued at $114,000 after purchasing an additional 1,146 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.